Key facts
- Minghui Pharmaceutical and Qilu Pharmaceutical announced updated clinical data for MHB088C (QLC5508).
- The data is from a Phase I/II study involving patients with heavily pretreated mCRPC.
- The results were presented at the 2026 ASCO Annual Meeting.
The announcement concerns updated clinical trial results for a drug candidate, MHB088C (QLC5508), developed by Minghui Pharmaceutical and Qilu Pharmaceutical. The data pertains to a Phase I/II study focused on patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) who have undergone extensive prior treatments. Presentation of this data at the ASCO Annual Meeting is significant for the oncology research community and investors in these companies.